Indaptus shares surge 26.92% intraday after agreeing to $6M securities purchase with David Lazar, who joins as co-CEO and chairman.

miércoles, 24 de diciembre de 2025, 10:37 am ET1 min de lectura
INDP--
Indaptus Therapeutics surged 26.92% intraday, as the company announced a securities purchase agreement with investor David Lazar, who purchased 1 million shares of convertible preferred stock at $6 per share, totaling $6 million, and immediately joined as co-CEO and chairman. The company focuses on developing systemically administered cancer and antiviral immunotherapies.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios